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Erythropoiesis is stimulated by the oxygen-regulated glycoprotein, erythropoietin (Epo). Erythrocytosis 
is a condition characterized by increased red cell mass and characteristically elevated hematocrit (Hct) 
and hemoglobin (Hb) concentration(1). Table 1 summarises its causes. When fully investigated 
(including genetic screening for known mutations), there remain a number of patients in whom no 
cause could be found, who are currently described as having idiopathic erythrocytosis. A large 
proportion of these have elevated or inappropriately normal (for the Hb level) serum Epo levels, 
suggesting an abnormality in oxygen sensing. Investigations have shown that several cases 
previously diagnosed as idiopathic erythrocytosis can now be attributed to mutations in genes involved 
in oxygen sensing(1).  
 
Here, we describe a patient who, following screening for known mutations in VHL, EGLN1 and 
EPAS1, was classified as having sporadic idiopathic erythrocytosis with raised Epo levels. This 
Caucasian man presented at the age of 27 with fatigue. His past medical and family history were 
unremarkable. He was a non-smoker with a 16-unit alcohol intake per week. He was found to have a 
high Hb concentration of 193 g/l, a red cell count of 6.53×1012/l, mean corpuscular volume (MCV) of 
89.7 fl, mean cell hemoglobin (MCH) of 29.9 pg, MCHC of 333 g/l, Hct of 0.586 l/l, white cell count 
(WCC) of 6.5×109/l – with a normal differential  – and platelets of 167×109/l. Red cell mass was 146% 
predicted. Vitamin B12 was 380 ng/l, folate was 8.9 mcg/l and ferritin was 58 mcg/l. Liver function tests 
revealed a slightly raised AST of 61 U/l and ALT 101 U/l. These subsequently normalized following 
significant weight loss but the Hb and Hct remained elevated. An abdominal ultrasound was normal. 
Hb electrophoresis was normal and revealed: HbF 0.5% and HbA2 2.8%. Serum Epo was 15.9 
mIU/ml (normal range: 2.5-10.5 mIU/ml). Arterial blood gas analysis found a carboxyhemoglobin of 
1.2% and a P50, the partial pressure of oxygen at which 50% of Hb is saturated with oxygen, was 
calculated at 23.91 mmHg (normal range: 27-33 mmHg, control sample: 32.7 mmHg), suggesting a 
mild leftward shift in the Hb-oxygen dissociation curve. He commenced low-dose aspirin and was 
treated with venesection every three to six months, aiming for Hct of less than 0.5 l/l.  Five years 
following his initial presentation, his disease etiology was revisited. In view of a high likelihood for a 
genetic etiology owing to his extreme phenotype of early onset, whole genome sequencing (WGS) 
was undertaken searching for causal mutations. Informed consent was obtained and procedures were 
performed in agreement with the Helsinki Declaration.  
 
WGS was performed as part of the “WGS500 project”, whereby 500 individuals with a variety of 
medical conditions of suspected genetic origin were sequenced to assess the clinical utility of WGS. It 
was conducted on the Illumina HiSeq2000 at a 30x sequencing depth. Reads were mapped to the 
human reference genome (hg19) using STAMPY(2), identification of alleles and variants was 
performed using the in-house software Platypus(3) and annotated using a pipeline based on 
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ANNOVAR(4). We searched for heterozygous or homozygous variants in candidate genes: HIF1A, 
EPAS1 (HIF2A), HIF3A, ARNT (HIF1B), HIF1AN (FIH), EGLN1 (PHD2), EGLN2 (PHD1), EGLN3 
(PHD3), VHL, EPO, EPOR, JAK2, HBB, HBA1, HBA2 and BPGM; or for rare coding mutations in any 
gene. Given the large number of genes involved in oxygen sensing and the regulation of 
erythropoiesis, and the growing evidence of new genes interacting with the HIF factors, whole genome 
sequencing was considered an appropriate and most informative investigation, compared with 
traditional methods of DNA sequencing which are impractical, lengthy and labor-intensive.  
 
A single novel heterozygous non-synonymous SNV was identified in the gene bisphosphoglycerate 
mutase (BPGM), at chr7:134346528. This was a G269A substitution, predicting the substitution of 
arginine at the evolutionarily conserved residue 90 with histidine (R90H). This mutation was not 
detected in any other samples sequenced in the WGS500 project, nor was it reported in the 1000 
genomes analysis. No other candidate gene coding variants were found in the patient’s genome.  It 
was validated by Sanger sequencing. To establish whether this arose de novo, we screened the 
patient’s parents and found that the mutation was inherited from his mother, who was also 
heterozygous (Figure 1). She had a [Hb] of 150 g/l and serum Epo level of 7.5 mIU/ml. A Polyphen 
score of 1.0 predicted that the R90H mutation is deleterious. Inspection of the 3D structure of BPGM 
suggests that replacement of arginine (R90) with histidine would potentially disrupt hydrogen bonds 
with backbone carbonyl groups, negatively affecting protein folding and stability (Figure 2). The 
functional effects of the mutation were confirmed by showing significantly lower levels of BPGM and its 
product 2,3-BPG in the red blood cells of both the patient and his mother (Table 2). BPGM was 
measured by the method Schröter and Kalinowsky, modified by Beutler(5), and 2,3-BPG by a 
modification of the method of Krimsky(6), as explained in Table 2.  
 
BPGM is the enzyme responsible for the synthesis of 2,3-BPG (from 1,3-BPG) in red blood cells(7). 
Normally 2,3-BPG is present at high concentrations (~5 mM) in red blood cells and binds the deoxy 
form of Hb to reduce its affinity for oxygen(8). BPGM deficiency leads to reduced levels of 2,3-BPG, 
resulting in a leftward shift in the hemoglobin-oxygen dissociation curve. Less available oxygen 
induces Epo production to stimulate red cell production and hence the development of erythrocytosis. 
Defects in BPGM have been associated both with hemolytic anemia(9) and erythrocytosis(10, 11). In 
1978, Rosa et al reported the first case of a 42-year old man with complete deficiency of BPGM and 
erythrocytosis(10). His Hb concentration was 190 g/l, his erythrocyte 2,3-BPG was below 3% of normal 
values and he had a low P50.  His sister also had complete BPGM deficiency and excessive 
erythrocytosis and they were both compound heterozygous with a SNV on one allele at codon 89 
(corresponding to codon 90 in the current reference genome) causing an arginine to cysteine 
substitution (R89C) resulting in low levels of an abnormal (inactive) BPGM protein and a deletion of 
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nucleotide 205 or 206 (codon 19) on the other allele, translating an aberrant product(12). In contrast, his 
son and daughter, who were heterozygous only for the R89C mutation, had intermediate phenotypes 
with partial BPGM deficiency and modest erythrocytosis(12). Garel et al reproduced the same functional 
defect in BPGM as the natural arginine-to-cysteine mutant in artificial mutants, Arg89Gly and 
Arg89Ser, produced by site-directed mutagenesis, giving evidence that indeed the arginine at this 
position is functionally important in the enzyme’s function(13). Only one other BPGM mutation, a 
homozygous Arg62Gln, was found in a male patient with erythrocytosis, who had concurrent G6-
phosphate dehydrogenase deficiency and evidence of consanguinity in his family(11). Indeed, 
mutations in BPGM are exceedingly rare. Recently, Bento et al sequenced 70 cases of idiopathic 
erythrocytosis, including sequencing of BPGM in cases with high Epo and no BPGM mutations were 
identified(14).  
 
It is of interest that the same amino acid residue (i.e. arginine at codon 90) is affected, as in previous 
cases of erythrocytosis(12). However, in our patient a different base substitution occurs, resulting in a 
novel amino acid substitution of arginine to histidine as opposed to arginine to cysteine in previous 
cases. This reinforces the findings of Garel et al(13) that the arginine residue at 90 is important for the 
function/stability of BPGM. Our patient, initially thought to be a sporadic case, inherited this mutation 
from his mother, who is also heterozygous. This is of interest for two reasons. One is that all previous 
erythrocytosis cases associated with BPGM mutations at the arginine 90 residue were not sporadic 
but rather were found in families with an autosomal dominant pattern of inheritance. The second is 
that, while the mother is also heterozygous for this mutation she is not polycythemic and has Epo 
levels within the normal range. One explanation for this could be that there is a second “hit” in the 
patient leading to compound heterozygosity as in Lemarchandel et al(12); however, WGS did not reveal 
any additional mutations/deletions in BPGM. Alternatively, the explanation could be that of variable 
penetrance of the disease-causing mutation, consistent with the phenotypes and patterns of 
inheritance of the family members in Lemarchandel et al. There, the index case and his sister, both 
compound heterozygotes, had complete BPGM deficiency and excessive erythrocytosis. His children, 
heterozygotes, had an intermediate phenotype, and his parents, at least one of whom was 
heterozygous for the arginine-to-cysteine mutation, were both healthy. Furthermore, while our patient’s 
mother is not polycythemic, her [Hb] lies at the upper end of the normal range and there is evidence of 
dysfunction in her red blood cells with low BPGM activity and 2,3-BPG levels, reinforcing that this 
mutation is functional. Given that heterozygous individuals, both in our study and in Lemarchandel et 
al, have intermediate levels of BPGM activity and 2,3-BPG levels, i.e. much higher than compound 
heterozygotes, the “variable penetrance” observed may simply be the result of variable effects 
reduced 2,3-BPG has on hemoglobin and the induction of erythropoiesis. It is also possible that the 
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variable effects of the heterozygous BPGM mutation relates to different expression ratios of wild-type 
versus mutant BPGM in different individuals.  
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Tables 
 
Table 1. Causes of Erythrocytosis. 
PRIMARY ERYTHROCYTOSIS (typically low Epo levels) 
Congenital 
Epo Receptor Mutations 
Acquired 
Polycythemia vera  
(including JAK2 mutations) 
SECONDARY ERYTHROCYTOSIS (high or normal Epo levels) 
Congenital (inherited) 
1. Defects in oxygen-sensing pathway: 
• VHL mutations (e.g. Chuvash 
Polycythemia) 
• EGLN1 (PHD2) mutations 
• EPAS1 (HIF2A) mutations 
 
2. Other congenital defects: 
• High-oxygen affinity Hb 
• Bisphosphoglycerate mutase 
deficiency 
Acquired (Epo-mediated) 
1. Systemic hypoxia: 
• Chronic lung disease 
• Right-to-left cardiopulmonary vascular 
shunts 
• Smoker’s erythrocytosis 
• Nocturnal hypoventilation syndromes 
(e.g. obstructive sleep apnea) 
• High altitude 
 
2. Local hypoxia: 
• Renal artery stenosis 
• Renal cysts (Polycystic kidney 
disease) 
• Post-renal transplant erythrocytosis 
 
3. Pathological Epo production (tumors) 
• Brain (cerebellar hemangioblastoma, 
meningioma) 
• Renal cell carcinoma 
• Hepatocellular carcinoma 
• Phaechromocytoma 
 
4. Drug-associated: 
• Erythropoietin/androgen 
administration 
 
adapted from McMullin, M. F. (2008) 
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Table 2. Results of BPGM and 2,3-BPG assays in red blood cells.
 
Patient 
(index case) Patient’s 
mother 
Control 
sample with 
comparable 
[Hb] 
Healthy control 
samples 
(n=10) At initial presentation 
At time of functional 
studies 
Hb (g/l) 
NR: 130 – 180 (Male), 115 
– 155 (Female) 
193 159 155 157 126.60 ± 19.04* 
BPGM (IU/g Hb) NA 3.62 3.27 4.21 4.99 ± 0.59* 
2,3-BPG 
(μmol/g Hb) NA 14.5 11.3 18.7 27.60 ± 6.75* 
RBC (x1012/l) 
NR: 4.5 – 6.5 (Male), 
3.9 – 5.6 (Female) 
6.5 6.5 5.2 5.2 4.14 ± 0.64* 
WBC (x109/l) 
NR: 4.0 – 11.0  6.5 4.2 7.0 6.3 7.99 ± 5.10* 
Platelets (×109/l) 
NR: 150 - 400 
167 210 230 177 307.30 ± 148.85* 
Epo  (miU/ml) 
NR: 2.5 – 10.5 15.9 NA 7.5 NA NA 
 
 
Figure Legends 
Figure 1. DNA sequence analysis detected a heterozygous G>A substitution at nucleotide c.269, in 
the patient and his mother but not his father. This predicts the substitution of arginine at residue 90 
with histidine (R90H). 
Figure 2. Structural effects. Inspection of the crystal structure of human BPGM (RCSB PDB id: 2HHJ, 
(15)) indicated that R90 is potentially involved in hydrogen bonds with carbonyl groups from E156 and 
W115, stabilizing the structure of the protein and the active site pocket (note proximity to phosphate 
group of 2,3-BPG). Figure produced using PyMOL (The PyMOL Molecular Graphics System, 
Schrödinger, LLC). 
 
 
 
 
* mean ± SD; Note that at the time of functional studies the patient’s Hb is lower owing to the fact that he had already commenced therapy 
with venesection at three-monthly intervals. 
 
BPGM was measured by the method Schröter and Kalinowsky, as modified by Beutler: Briefly, an equilibrium mixture of F-1,6-biP, GAP, 
DHAP, 1,3-BPG, NAD and NADH is established. Addition of hemolysate containing BPGM causes the removal of 1,3-BPG, displacement 
of the GAP/1,3-BPG equilibrium and the reduction of NAD to NADH, which is monitored by the increase in absorbance at 340 nm. The 
2,3-BPG was measured by a modification of the method of Krimsky: Briefly, an equilibrium mixture of PEP, enolase, 2-PGA, PGAM-1 and 
3-PGA is formed. Addition of red cell extract containing 2,3-BPG, the obligatory cofactor for PGAM-1 activity, causes depletion of PEP, 
which is monitored by the decrease in absorbance at 240 nm. 
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